Human Intervention Study for Validating Foods With Improved Nutrient Profile
1 other identifier
interventional
60
1 country
1
Brief Summary
The proposed intervention study is designed to evaluate the physiological impact of the regular consumption of the developed foods with improved nutrient profile (verum) in comparison to commercial available foods (control) by a controlled, randomized, double-blind crossover study with patients with measurable cardiovascular risk factors (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / Triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2019
CompletedFirst Posted
Study publicly available on registry
October 3, 2019
CompletedStudy Start
First participant enrolled
October 29, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 16, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 23, 2020
CompletedMarch 25, 2020
September 1, 2019
5 months
October 1, 2019
March 24, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
LDL cholesterol
cardiovascular risk factor
change from baseline after 4 weeks
Secondary Outcomes (34)
blood lipids
change from baseline after 4 weeks
anthropometric data
change from baseline after 4 weeks
blood pressure
change from baseline after 4 weeks
lipoprotein a
change from baseline after 4 weeks
high-sensitive c-reactive protein
change from baseline after 4 weeks
- +29 more secondary outcomes
Study Arms (2)
verum
EXPERIMENTALThe food range is comprised of: sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)
control
ACTIVE COMPARATORIn the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
Interventions
The food range is comprised of: sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week
Eligibility Criteria
You may qualify if:
- females and males
- BMI \< 30 kg/m2
- subjects must be able and willing to give written informed consent, and to comply with study procedures
- Participants following a traditional Western diet composed of dairy products, sausage, meat, fast foods, chocolate and snacks, cereals, vegetables, and fruits (PAL: 1.6)
- Precondition: Stable eating habits of at least one years before enrolment
- subjects with moderate elevated LDL cholesterol (≥ 3 mmol/l) and triacylglyceride concentrations (≥ 1.5 mmol/l) in plasma, without lipid-lowering medication
- stable dose of antihypertensive medication for \> 3 months before study and during the entire study period or without antihypertensive medication
- subjects must have adequate fluency in the German language to complete the questionnaires and understand the nutritional recommendations
You may not qualify if:
- subjects with any acute or chronic disease (CVD, tumor, infection, other), gastrointestinal diseases, diabetes mellitus (type I and II), chronic renal disease, diseases of the parathyroid, diseases necessitating regular phlebotomies other chronic diseases which could affect the results of the present study
- use of prescription medicine which could affect results of the study, including systemic glucocorticoids
- intake of lipid-lowering drugs, diabetes medication, hormone replacement therapy
- estimated glomerular filtration (eGFR) rate \< 60 ml/min
- weight loss (≤ 3 kg) or weight gain (≥ 3 kg) during the last three months before study begin
- pregnancy or lactation
- transfusion of blood in the last three months before blood sample taking
- use of dietary supplements incl. multivitamins, fish oil capsules, minerals, and trace elements (three months before and during the entire study period)
- vegetarians, vegans, food allergies (e.g. milk, nuts etc.)
- dependency on alcohol or drugs
- elite athletes (\>10 hours of strenuous physical activity per week)
- simultaneous participation in other clinical studies
- inability (physically or psychologically) to comply with the procedures required by the protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Friedrich Schiller University
Jena, Thuringia, 07743, Germany
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Christine Dawczynski, PhD
University of Jena
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Masking Details
- The foods are offered in neutral packaging and are provided regularly by the study team. All personal (participants, care provider) are blinded.
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
October 1, 2019
First Posted
October 3, 2019
Study Start
October 29, 2019
Primary Completion
March 16, 2020
Study Completion
March 23, 2020
Last Updated
March 25, 2020
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share